XELOX for Metastatic Breast Cancer

Phase 2

Completed

• Conditions: Metastatic Breast Cancer

• Registration Number: NCT00204776
• Lead Sponsor: University of Wisconsin, Madison

Brief Summary

Both capecitabine and oxaliplatin have single agent activity in breast cancer. The combination has improved activity in other solid tumors. This study seeks to assess the activity of the combination in breast cancer.

Detailed Description

Not available

Study Timeline

• Study Start: 2005-03
• Study First Submitted: 2005-09-12
• Study First Submitted QC: 2005-09-13
• Study First Posted: 2005-09-20
• Study Completion: 2006-11
• Status Verified: 2018-12
• Last Update Submitted: 2019-12-11
• Last Update Posted: 2019-12-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 37

Inclusion Criteria

• preserved organ function
• good performance status
• no more than one prior therapy
• no active brain metastasis

Exclusion Criteria

• No prior capecitabine or oxaliplatin
• no con-current therapy

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Overall response rate

Secondary Outcome Measures

Name	Time	Method
Toxicity
Time to progression

Trial Locations

Locations (1)

University of Wisconsin; 🇺🇸 Madison, Wisconsin, United States